anti-Chemokine (C-C Motif) Receptor 9 (CCR9) Anticorps

The protein encoded by CCR9 is a member of the beta chemokine receptor family. De plus, nous expédions Chemokine (C-C Motif) Receptor 9 Protéines (4) et et beaucoup plus de produits pour cette protéine.

afficher tous les anticorps Gène GeneID UniProt
CCR9 10803 P51686
CCR9 12769 Q9WUT7
CCR9 282832  
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top anti-Chemokine (C-C Motif) Receptor 9 Anticorps sur anticorps-enligne.fr

Showing 10 out of 104 products:

Catalogue No. Reactivité Hôte Conjugué Application Images Quantité Livraison Prix Détails
Souris Rat Inconjugué ICC, IHC (fro), FACS, IF 1 mL 7 to 8 Days
$510.24
Détails
Humain Lapin Inconjugué IHC (p) Anti-CCR9 antibody  ABIN1048406 IHC staining of human thymus. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. 50 μg 11 to 14 Days
$484.00
Détails
Humain Lapin Inconjugué IHC, IHC (p) Anti-CCR9 antibody  ABIN1048405 IHC staining of human thymus, lymphocytes. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Anti-CCR9 antibody IHC of human Lymph Node, Hodgkins Lymphoma. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. 50 μg 11 to 14 Days
$484.00
Détails
Roussette (Chauve-souris) Lapin Inconjugué IHC, IHC (p) Anti-CCR9 antibody  ABIN1048407 IHC staining of human thymus, lymphocytes. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Anti-CCR9 antibody IHC of human Lymph Node, Hodgkins Lymphoma. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. 50 μg 11 to 14 Days
$484.00
Détails
Humain Lapin Inconjugué ELISA, ICC, IF, WB Western blot analysis of CCR9 using HeLa whole cell lysates ABIN6274000 staining HepG2 by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary antibody. 100 μL 11 to 12 Days
$390.77
Détails
Humain Lapin Inconjugué WB 100 μg 4 to 6 Days
$240.00
Détails
Souris Rat Inconjugué FACS, IF 1 mL 11 to 14 Days
$676.50
Détails
Souris Souris Biotin FACS 50 μg 11 to 14 Days
$375.83
Détails
Souris Souris FITC FACS 100 μg 11 to 14 Days
$478.50
Détails
Souris Souris PE FACS 100 μg 11 to 14 Days
$581.17
Détails

anti-Chemokine (C-C Motif) Receptor 9 Anticorps mieux référencés

  1. Human Monoclonal CCR9 Primary Antibody pour FACS - ABIN4895572 : Sundström, Ahlmanner, Akéus, Sundquist, Alsén, Yrlid, Börjesson, Sjöling, Gustavsson, Wong, Quiding-Järbrink: Human Mucosa-Associated Invariant T Cells Accumulate in Colon Adenocarcinomas but Produce Reduced Amounts of IFN-γ. dans Journal of immunology (Baltimore, Md. : 1950) 2015 (PubMed)
    Show all 7 Pubmed References

  2. Mouse (Murine) Monoclonal CCR9 Primary Antibody pour CyTOF, FACS - ABIN4899103 : Ueha, Murai, Yoneyama, Kitabatake, Imai, Shimaoka, Yonehara, Ishikawa, Matsushima: Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects. dans Journal of leukocyte biology 2006 (PubMed)
    Show all 6 Pubmed References

  3. Human Monoclonal CCR9 Primary Antibody pour CyTOF, FACS - ABIN4899104 : Minang, Trivett, Bolton, Trubey, Estes, Li, Smedley, Pung, Rosati, Jalah, Pavlakis, Felber, Piatak, Roederer, Lifson, Ott, Ohlen et al.: Distribution, persistence, and efficacy of adoptively transferred central and effector memory-derived autologous simian immunodeficiency virus-specific CD8+ T cell clones in rhesus macaques during ... dans Journal of immunology (Baltimore, Md. : 1950) 2009 (PubMed)
    Show all 6 Pubmed References

  4. Monoclonal CCR9 Primary Antibody pour FACS, IHC (fro) - ABIN534156 : Lee, Logronio, Tu, Zhai, Ni, Mei, Dilley, Yu, Rajpal, Brown, Appah, Chin, Han, Affolter, Lin: Anti-IL-7 receptor-? reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. dans Proceedings of the National Academy of Sciences of the United States of America 2012 (PubMed)
    Show all 3 Pubmed References

  5. Human Monoclonal CCR9 Primary Antibody pour FACS - ABIN4895570 : Johnson-Holiday, Singh, Johnson, Singh, Stockard, Grizzle, Lillard: CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. dans International journal of oncology 2011 (PubMed)
    Show all 3 Pubmed References

  6. Mouse (Murine) Monoclonal CCR9 Primary Antibody pour FACS - ABIN4895580 : Takeuchi, Yokota, Ohoka, Kagechika, Kato, Song, Iwata: Efficient induction of CCR9 on T cells requires coactivation of retinoic acid receptors and retinoid X receptors (RXRs): exaggerated T Cell homing to the intestine by RXR activation with organotins. dans Journal of immunology (Baltimore, Md. : 1950) 2010 (PubMed)
    Show all 3 Pubmed References

  7. Human Polyclonal CCR9 Primary Antibody pour FACS, IHC (p) - ABIN152131 : Zaballos, Gutiérrez, Varona, Ardavín, Márquez: Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. dans Journal of immunology (Baltimore, Md. : 1950) 1999 (PubMed)
    Show all 2 Pubmed References

  8. Mouse (Murine) Monoclonal CCR9 Primary Antibody pour FACS - ABIN4895574 : Uematsu, Fujimoto, Jang, Yang, Jung, Nishiyama, Sato, Tsujimura, Yamamoto, Yokota, Kiyono, Miyasaka, Ishii, Akira: Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. dans Nature immunology 2008 (PubMed)
    Show all 2 Pubmed References

  9. Mouse (Murine) Monoclonal CCR9 Primary Antibody pour FACS - ABIN2472924 : De Jongh, Warner, Colvin, Catterall: Characterization of the two size forms of the alpha 1 subunit of skeletal muscle L-type calcium channels. dans Proceedings of the National Academy of Sciences of the United States of America 1992 (PubMed)
    Show all 3 Pubmed References

  10. Mouse (Murine) Monoclonal CCR9 Primary Antibody pour FACS - ABIN2472925 : Uehara, Hayes, Li, El-Khoury, Canelles, Fowlkes, Love: Premature expression of chemokine receptor CCR9 impairs T cell development. dans Journal of immunology (Baltimore, Md. : 1950) 2005 (PubMed)
    Show all 3 Pubmed References

Plus d’anticorps contre Chemokine (C-C Motif) Receptor 9 partenaires d’interaction

Human Chemokine (C-C Motif) Receptor 9 (CCR9) interaction partners

  1. There were significantly increased CCR9 protein levels in failing human hearts.

  2. this study showed that CCR7 are overexpressed in CD4(-) CD8(-) thymocytes of myasthenia gravis patients.

  3. Results indicated that the expression levels of CCR9 in lesional skin may be a useful biologic marker of the clinical efficacy of infliximab therapy in psoriasis patients.

  4. Xray crystal structure of the CCR9 receptor in complex with vercirnon at 2.8 A resolution

  5. It plays a pathogenic role in liver diseases and it will be a therapeutic target of the diseases.

  6. that CCL25/CCR9 signal may provide cancer cells with chemotactic abilities through influencing several epithelial-mesenchymal transitionmarkers

  7. Studies indicate important roles played by chemokine ligand 25 (CCL25)/chemokine receptor 9 (CCR9) in tumorigenesis, tumor chemoresistance and metastasis.

  8. CCR9 and Integrin-beta7 expression has a differential effect on graft fate during acute graft-versus-host disease (GVHD) of the liver depending on the GVHD target tissue.

  9. CCR9 mRNA and protein levels were significantly increased in the nasopharyngeal carcinoma group compared with the control group.

  10. CCR9-CCL25 interaction promoted proliferation and suppressed apoptosis of non-small cell lung cancer cells by activating the PI3K/Akt pathway.

  11. CCR9 could be beneficial in predicting lymph node metastasis, and it might act as a novel prognostic biomarker for lung adenocarcinoma.

  12. We also show that primary tumors can be modeled in immunocompetent mice by microinjecting CCR9-expressing cancer cell lines into early-stage mouse blastocysts, which induces central immune tolerance

  13. High CCR9 expression is associated with the pathogenesis of ulcerative colitis.

  14. Expression of CCR9 and CCL25, the only natural ligand of CCR9, was significantly higher (p<0.0001) in NSCLC tissues and serum respectively, compared to their respective controls.

  15. activation of Notch1 has a dominant-negative effect on Ccr9 transcription and that Notch1 and E proteins control the dynamic expression of Ccr9 during T cell development.

  16. The results show the potential of the 91R monoclonal antibody as a therapeutic agent for treatment of CCR9-expressing tumors.

  17. results suggest that CCR9 can act as a novel prognostic marker and therapeutic target for hepatocellular carcinoma

  18. CCR9 expression is elevated in the nodal lymphomas of patients with GI involvement

  19. Only rotavirus specific CD4 T cells expressed intestinal homing receptors alpha4beta7 and CCR9.

  20. Data suggest that P-glycoprotein associate with the F-actin cytoskeleton through ezrin/radixin/moesin (ERM) in CCR9/CCL25 induced multidrug resistance of acute T-lymphocytic leukemia (T-ALL) cells.

Mouse (Murine) Chemokine (C-C Motif) Receptor 9 (CCR9) interaction partners

  1. these results showed a site- and cell-specific expressions of Ccl25 and its receptor Ccr9 within both maternal and embryonic compartments of implantation sites and suggested a role in inducing specific Ccr9+ leukocytes at the maternal-fetal interface during the initial steps of embryo implantation in the mouse model

  2. Abrogation of CCR9 improved the post-myocardial infarction survival rate and left ventricular (LV) dysfunction and decreased the infarct size. The data reveal that CCR9 serves as a novel modulator of pathological progression following myocardial infarction through NF-kappaB and MAPK signaling.

  3. Pressure overload-induced hypertrophy was greatly attenuated by CCR9 deficiency in cardiac-specific CCR9 knockout mice, whereas CCR9 overexpression in cardiac-specific transgenic mice strikingly enhanced cardiac hypertrophy.

  4. CCR9 and CCL25 expressions are induced in the early stages of airway inflammation and they have an important role modulating eosinophils and lymphocytes recruitment at the first stages of inflammatory process

  5. CCR9 and Integrin-beta7 expression has a differential effect on graft fate during acute graft-versus-host disease (GVHD) of the liver depending on the GVHD target tissue.

  6. data indicate that in addition to acting as a gut-homing molecule, CCR9 signaling shapes immune responses by inhibiting Treg cell development

  7. Data suggest that blocking CC chemokine receptor 9 (CCR9) may represent a novel safe therapy for rheumatoid arthritis (RA).

  8. activation of Notch1 has a dominant-negative effect on Ccr9 transcription and that Notch1 and E proteins control the dynamic expression of Ccr9 during T cell development.

  9. CCR9/CCL25 is involved in acute skin transplantation rejection and anti-CCL25 strategies might be useful in preventing acute rejection.

  10. Accumulated CD11b(+) macrophages are critical for activating hepatic stellate cells through the CCR9/CCL25 axis and therefore promote liver fibrosis.

  11. CCR9-expressed plasmacytoid dendritic cells are possibly small intestine regulatory, antigen-presenting cells that suppress intestinal inflammation.

  12. CCR9 is required for recruitment of peritoneal macrophages in the steady state to control systemic sepsis during early phases of peritoneal infection.

  13. Data show that chemokine receptor CCR9(-/-) knockout mice developed a chronic inflammatory response with over-expression of the cytokines and chemokines.

  14. characterization of expression and thymus-expressed chemokine responsiveness of the murine thymus, spleen and mesenteric lymph node

  15. CCR9(+) macrophages contribute to the induction of acute liver inflammation in mouse models of hepatitis.

  16. CCL25/CCR9 interactions regulate inflammatory immune responses in the large intestinal mucosa by balancing different subsets of dendritic cells.

  17. Three chemokine receptors, Ccr9, Ccr7, and Cxcr4, cooperatively regulate homing of hematopoietic progenitors to the embryonic mouse thymus.

  18. Signaling of the chemokine CCL25 through its receptor CCR9 induces Tregs to migrate to the intestine.

  19. CCR9+ Th cells are a subset of IL-21-producing T helper cells that influence regional specification of autoimmune diseases that affect accessory organs of the digestive system

  20. Critical role of chemokine receptor signaling in thymic settling.

Chemokine (C-C Motif) Receptor 9 (CCR9) profil antigène

Profil protéine

The protein encoded by this gene is a member of the beta chemokine receptor family. It is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. Chemokines and their receptors are key regulators of the thymocytes migration and maturation in normal and inflammation conditions. The specific ligand of this receptor is CCL25. It has been found that this gene is differentially expressed by T lymphocytes of small intestine and colon, suggested a role in the thymocytes recruitment and development that may permit functional specialization of immune responses in different segment of the gastrointestinal tract. This gene is mapped to the chemokine receptor gene cluster region. Two alternatively spliced transcript variants have been described. Multiple transcript variants encoding different isoforms have been found for this gene.

Gene names and symbols associated with CCR9

  • C-C motif chemokine receptor 9 (CCR9) anticorps
  • chemokine (C-C motif) receptor 9 (Ccr9) anticorps
  • C-C motif chemokine receptor 9 (Ccr9) anticorps
  • A130091K22Rik anticorps
  • CC-CKR-9 anticorps
  • CDw199 anticorps
  • Cmkbr10 anticorps
  • GPR-9-6 anticorps
  • GPR28 anticorps

Protein level used designations for CCR9

C-C chemokine receptor type 9 , G protein-coupled receptor 28 , C-C CKR-9 , CC-CKR-9 , CCR-9 , chemokine C-C receptor 10 , chemokine C-C motif receptor 9

GENE ID SPECIES
10803 Homo sapiens
12769 Mus musculus
484793 Canis lupus familiaris
100065535 Equus caballus
530951 Bos taurus
678667 Ovis aries
282832 Rattus norvegicus
713934 Macaca mulatta
414377 Sus scrofa
Fournisseurs de qualité sélectionnés pour anti-Chemokine (C-C Motif) Receptor 9 (CCR9) Anticorps
Avez-vous cherché autre chose?